Innovent Biologics (HK:1801) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innovent Biologics has received approval from China’s National Medical Products Administration for its new drug, DOVBLERON, a next-generation ROS1 inhibitor for treating advanced ROS1-positive non-small cell lung cancer. This addition bolsters Innovent’s portfolio and offers a promising option for patients with limited treatment choices. The approval follows successful trials demonstrating DOVBLERON’s efficacy in addressing unmet needs in lung cancer treatment.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.